CO5261555A1 - Linezolid-forma cristalina ii - Google Patents

Linezolid-forma cristalina ii

Info

Publication number
CO5261555A1
CO5261555A1 CO01005901A CO01005901A CO5261555A1 CO 5261555 A1 CO5261555 A1 CO 5261555A1 CO 01005901 A CO01005901 A CO 01005901A CO 01005901 A CO01005901 A CO 01005901A CO 5261555 A1 CO5261555 A1 CO 5261555A1
Authority
CO
Colombia
Prior art keywords
linezolid
crystal form
oxazolidinyl
mfi
jpeg
Prior art date
Application number
CO01005901A
Other languages
English (en)
Spanish (es)
Inventor
Michael David Bergren
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22658183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5261555(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of CO5261555A1 publication Critical patent/CO5261555A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18Oxygen atoms
    • C07D263/20Oxygen atoms attached in position 2
    • C07D263/22Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CO01005901A 2000-02-02 2001-01-26 Linezolid-forma cristalina ii CO5261555A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17983700P 2000-02-02 2000-02-02

Publications (1)

Publication Number Publication Date
CO5261555A1 true CO5261555A1 (es) 2003-03-31

Family

ID=22658183

Family Applications (1)

Application Number Title Priority Date Filing Date
CO01005901A CO5261555A1 (es) 2000-02-02 2001-01-26 Linezolid-forma cristalina ii

Country Status (30)

Country Link
EP (1) EP1255754B1 (cg-RX-API-DMAC7.html)
JP (1) JP5235256B2 (cg-RX-API-DMAC7.html)
KR (3) KR100864745B1 (cg-RX-API-DMAC7.html)
CN (1) CN1221547C (cg-RX-API-DMAC7.html)
AR (1) AR027261A1 (cg-RX-API-DMAC7.html)
AT (1) ATE297920T1 (cg-RX-API-DMAC7.html)
AU (1) AU782138B2 (cg-RX-API-DMAC7.html)
BR (1) BR0107667A (cg-RX-API-DMAC7.html)
CA (1) CA2395603C (cg-RX-API-DMAC7.html)
CO (1) CO5261555A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ302292B6 (cg-RX-API-DMAC7.html)
DE (1) DE60111497T2 (cg-RX-API-DMAC7.html)
DK (1) DK1255754T3 (cg-RX-API-DMAC7.html)
EA (1) EA004434B1 (cg-RX-API-DMAC7.html)
EE (1) EE05197B1 (cg-RX-API-DMAC7.html)
ES (1) ES2242728T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0301076A3 (cg-RX-API-DMAC7.html)
IL (1) IL151010A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA02007471A (cg-RX-API-DMAC7.html)
MY (1) MY122829A (cg-RX-API-DMAC7.html)
NO (2) NO323459B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ520541A (cg-RX-API-DMAC7.html)
PE (1) PE20011086A1 (cg-RX-API-DMAC7.html)
PL (1) PL356433A1 (cg-RX-API-DMAC7.html)
PT (1) PT1255754E (cg-RX-API-DMAC7.html)
SI (1) SI1255754T1 (cg-RX-API-DMAC7.html)
SK (1) SK287025B6 (cg-RX-API-DMAC7.html)
TW (1) TWI297687B (cg-RX-API-DMAC7.html)
WO (1) WO2001057035A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200205162B (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100490643B1 (ko) * 2002-10-29 2005-05-19 한국과학기술연구원 새로운 메틸리덴 피페리딘일 옥사졸리딘온 유도체 및이들의 제조방법
ES2803516T3 (es) 2003-10-16 2021-01-27 Symed Labs Ltd Una forma cristalina de linezolid
ES2294494T3 (es) 2004-04-19 2008-04-01 Symed Labs Limited Un nuevo procedimiento para la preparacion de linezolid y compuestos relacionados.
WO2006110155A1 (en) * 2004-06-29 2006-10-19 Teva Pharmaceutical Industries Ltd Solid forms of linezolid and processes for preparation thereof
CA2572054A1 (en) * 2004-06-29 2006-01-12 Teva Pharmaceutical Industries Ltd. Crystalline form iv of linezolid
CA2602073A1 (en) * 2005-02-24 2006-08-31 Teva Pharmaceutical Industries Ltd. Processes for the preparation of linezolid intermediate
JP2008514734A (ja) * 2005-06-22 2008-05-08 テバ ファーマシューティカル インダストリーズ リミティド マレイン酸テガセロドの多型体
PL1749517T3 (pl) * 2005-07-20 2008-12-31 Teva Pharma Trwała farmaceutyczna kompozycja zawierająca linezolid
WO2007102082A1 (en) * 2006-03-09 2007-09-13 Glenmark Pharmaceuticals Limited High oxazolidinone content solid dosage forms
US20080139563A1 (en) * 2006-10-23 2008-06-12 Concert Pharmaceuticals Inc. Oxazolidinone derivatives and methods of use
WO2011050826A1 (en) 2009-10-28 2011-05-05 Synthon B.V. Process for making crystalline form a of linezolid
JP5865898B2 (ja) 2010-04-30 2016-02-17 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation リネゾリドを調製するためのプロセス
EP2690100A1 (en) 2010-08-11 2014-01-29 Synhton B.V. Process for making linezolid
EP2603505A1 (en) 2010-08-11 2013-06-19 Synthon BV Process for making linezolid
CN103402990A (zh) * 2011-02-24 2013-11-20 李药业有限公司 无水利奈唑胺晶型-ii
WO2012119653A1 (en) 2011-03-09 2012-09-13 Synthon Bv Process for making crystalline form a of linezolid
CN102731341A (zh) * 2011-04-13 2012-10-17 上海医药工业研究院 用于制备利奈唑胺的中间体及其制备方法
CN102766106A (zh) * 2011-05-03 2012-11-07 江苏豪森医药集团有限公司 利奈唑胺的新晶型及其制备方法
CN102399200B (zh) * 2011-12-14 2013-12-04 浙江新东港药业股份有限公司 一种利用悬浮结晶法制备利奈唑胺晶型ⅰ的方法
IN2014DN06213A (cg-RX-API-DMAC7.html) 2012-01-24 2015-10-23 Jubilant Life Sciences Ltd
WO2013120496A1 (en) 2012-02-14 2013-08-22 Pharmathen S.A. Process for the preparation of linezolid in crystalline form and salts thereof
CN102643245A (zh) * 2012-04-10 2012-08-22 杭州华东医药集团生物工程研究所有限公司 一种利奈唑胺晶型及其制备方法
WO2014071990A1 (en) 2012-11-09 2014-05-15 Synthon Bv Process for making linezolid
KR102615354B1 (ko) 2016-11-16 2023-12-21 페르시카 파마슈티컬스 리미티드 요통을 위한 항생제 제형
RU2771279C2 (ru) 2017-11-16 2022-04-29 Персика Фармасьютикалз Лтд. Композиции линезолида

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK283420B6 (sk) * 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
MY115155A (en) * 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
SG85683A1 (en) * 1996-04-11 2002-01-15 Upjohn Co Process to prepare oxazolidinones
EE04370B1 (et) * 1997-11-07 2004-10-15 Pharmacia & Upjohn Company Oksasolidinoonide valmistamismeetod, meetodis kasutatavad vaheühendid ja nende valmistamine

Also Published As

Publication number Publication date
AU3275501A (en) 2001-08-14
CZ20022635A3 (cs) 2002-10-16
PT1255754E (pt) 2005-11-30
DE60111497D1 (de) 2005-07-21
KR20070087178A (ko) 2007-08-27
NO20023654D0 (no) 2002-08-01
EA200200819A1 (ru) 2003-02-27
CA2395603A1 (en) 2001-08-09
EE05197B1 (et) 2009-08-17
ES2242728T3 (es) 2005-11-16
ATE297920T1 (de) 2005-07-15
PL356433A1 (en) 2004-06-28
EP1255754A1 (en) 2002-11-13
SK287025B6 (sk) 2009-10-07
KR100781815B1 (ko) 2007-12-03
AR027261A1 (es) 2003-03-19
KR20080044358A (ko) 2008-05-20
NO20065836L (no) 2002-08-01
CN1394207A (zh) 2003-01-29
SK9942002A3 (en) 2002-11-06
IL151010A0 (en) 2003-02-12
CA2395603C (en) 2010-03-23
NO20023654L (no) 2002-08-01
CN1221547C (zh) 2005-10-05
HK1051196A1 (en) 2003-07-25
AU782138B2 (en) 2005-07-07
TWI297687B (en) 2008-06-11
KR100864745B1 (ko) 2008-10-22
SI1255754T1 (sl) 2005-12-31
EE200200420A (et) 2003-12-15
KR20020072300A (ko) 2002-09-14
EP1255754B1 (en) 2005-06-15
ZA200205162B (en) 2003-09-29
MXPA02007471A (es) 2002-12-13
EA004434B1 (ru) 2004-04-29
CZ302292B6 (cs) 2011-02-09
MY122829A (en) 2006-05-31
DE60111497T2 (de) 2006-05-18
NO323459B1 (no) 2007-05-14
NZ520541A (en) 2004-02-27
HUP0301076A3 (en) 2004-06-28
BR0107667A (pt) 2002-10-08
PE20011086A1 (es) 2001-10-04
JP5235256B2 (ja) 2013-07-10
HUP0301076A2 (hu) 2003-08-28
DK1255754T3 (da) 2005-08-22
WO2001057035A1 (en) 2001-08-09
JP2003522175A (ja) 2003-07-22

Similar Documents

Publication Publication Date Title
CO5261555A1 (es) Linezolid-forma cristalina ii
DE60329287D1 (de) Boehmitteilchen und diese enthaltende polymermaterialien
CY1105055T1 (el) Θepαπεια γαστρεντepικων στρωματικων ογκων
JP2003522175A5 (cg-RX-API-DMAC7.html)
GB0315111D0 (en) Substituted 5-membered ring compounds and their use
MY132094A (en) Pyrrolo-triazine aniline compounds useful as kinase inhibitors
GEP20094675B (en) Heteroaryl- tetra-hydropiperidyl compounds useful for treating or preventing pain
NO992226L (no) Nye forbindelser for anvendelse som neuro-protektive midler
PT1663236E (pt) Combinação compreendendo n-(3-metoxi-5-metilpirazin-2-il)-2-(4- [1,3,4-oxadiazol-2-il]fenil)piridina-3-sulfonamida e um bifosfonato
SI1526132T1 (sl) Substituirani derivati oksazolidinona in njihova uporaba kot inhibitorji faktorja Xa
ATE302762T1 (de) Oxazolidinon-thioamide mit piperazinamid- substituenten
TR199800679T2 (xx) Kiral metil fenil oksazolidinon.
NZ332990A (en) oral pharmaceutical composition containing a H+, K+-atpase inhibitor having a extended blood plasma profile
SE0004053D0 (sv) N-type calcium channel antagonists for the treatment of pain
DK1301207T3 (da) Sammensætninger til behandling af bakterieinfektioner indeholdende en oxazolidinonforbindelse, sulbactam og ampicillin
PT1545710E (pt) Utilização de n-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil) piridino-3-sulfonamida no tratamento de cancro
FR2846329B1 (fr) Derives de pyridoindolone substitues en -3 par un phenyle, leur preparation et leur application en therapeutique
PL359847A1 (pl) Kompozycja w postaci cząstek, zawierająca eletryptan, o kontrolowanym uwalnianiu według profilu sigmoidalnego
ATE412413T1 (de) Oxazolidin tablettenformulierung
AR028032A1 (es) Aparato para cortar y revolver cuajada
TR200102984T2 (tr) Madraftalazin trevlerinin ”n iltihaplandìrìcì sitokinlerin engelleyicileri olarak kullanìmì
RU97109697A (ru) БРОМИД 1-/β-ФЕНИЛЭТИЛ/-4-/П-ДИМЕТИЛАМИНОБЕНЗИЛИДЕНАМИНО/-1,2,4-ТРИАЗОЛИЯ, ОБЛАДАЮЩИЙ АНТИИШЕМИЧЕСКИМ, АНТИОКСИДАНТНЫМ, β-АДРЕНОБЛОКАТОРНЫМ, УТЕРОТОНИЧЕСКИМ И СНИЖАЮЩИМ ВНУТРИГЛАЗНОЕ ДАВЛЕНИЕ ДЕЙСТВИЕМ
SE0004055D0 (sv) N-type calcium channel antagonists for the treatment of pain
ATE323066T1 (de) Phenyl-und phenylalkyl-substituierte ethanolamine und ethylendiamine
EA200300835A1 (ru) Новые производные алкилфенилиминоимидазолидина для лечения недержания мочи

Legal Events

Date Code Title Description
FC Application refused